SCHEMBL3106796

SCHEMBL3106796

Cc1oc(-c2ccc(F)cc2)cc1C(O)C1CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.40
RAB9A P51151 4/20 0.40
TDP1 Q9NUW8 1/20 0.38
BRD4 O60885 2/20 0.37
GSK3B P49841 2/20 0.35
ACKR3 P25106 1/20 0.35
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
MMP13 P45452 2/20 0.34
MAPT P10636 1/20 0.34
MAPK1 P28482 1/20 0.33
PDE2A O00408 1/20 0.33
PAX8 Q06710 1/20 0.33
MEN1 O00255 1/20 0.33
S1PR1 P21453 1/20 0.33
KMT2A Q03164 1/20 0.33
PRKDC P78527 1/20 0.33
IDO1 P14902 1/20 0.32
TDO2 P48775 1/20 0.32
KDR P35968 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3095713 0.87 NPC1 (0.45) NPC1RAB9ABRD4GSK3BCNR1
SCHEMBL3113043 0.86 ALDH1A1 (0.39) NPC1RAB9ATDP1BRD4MAPT
SCHEMBL3109809 0.86 PDE2A (0.45) BRD4MAPTMAPK1PDE2APAX8
SCHEMBL3095541 0.85 ALDH1A1 (0.40) NPC1RAB9ATDP1BRD4MAPT
SCHEMBL3102426 0.85 MMP13 (0.45) NPC1RAB9AGSK3BCNR1CNR2
SCHEMBL3109648 0.84 BRD4 (0.39) NPC1RAB9ABRD4MEN1S1PR1
SCHEMBL3095575 0.84 NPC1 (0.38) NPC1RAB9ATDP1GSK3BACKR3
SCHEMBL3104373 0.84 BRD4 (0.36) BRD4IDO1TDO2
SCHEMBL3110115 0.84 IDO1 (0.36) NPC1RAB9ABRD4PDE2AIDO1
SCHEMBL3109064 0.84 ACKR3 (0.38) NPC1RAB9AACKR3PDE2AIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2210876-B1 HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST TAKEDA PHARMACEUTICAL (JP) 2015-05-20 EP disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 US disclosed
EP-2210876-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256156-A1 HETEROCYCLIC COMPOUND GLP1R, GPR119, GCGR NPC1 3994/4885RAB9A 3790/4885TDP1 4801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.